Evidence map›Paper›PMID 26063956›Full record

ArticleDisease markers2015

Circulating MicroRNA-21 Is a Potential Diagnostic Biomarker in Gastric Cancer.

Jianhong Wu, Guangxin Li, Zeyou Wang, Yongliang Yao, Rui Chen, XiongYong Pu, Jianjun Wang

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Disease markers, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 5 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 5 syntheses or guidelines pooled it, 103 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Circ_0004592: An auxiliary diagnostic biomarker for gastric cancer.World journal of gastrointestinal oncology · 2024
    Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Jianhong WuDepartment of Clinical Laboratory, Kunshan First People's Hospital, Jiangsu University, Kunshan 215300, China.
Guangxin LiDepartment of Pathology, Chongqing Cancer Institute, Chongqing 400030, China.
Zeyou WangInstitute of Cancer Research, Central South University, Changsha 410078, China.
Yongliang YaoDepartment of Clinical Laboratory, Kunshan First People's Hospital, Jiangsu University, Kunshan 215300, China.
Rui ChenDepartment of Pathology, Chongqing Cancer Institute, Chongqing 400030, China.
XiongYong PuDepartment of Clinical Laboratory, Kunshan First People's Hospital, Jiangsu University, Kunshan 215300, China.
Jianjun WangDepartment of Clinical Laboratory, Kunshan First People's Hospital, Jiangsu University, Kunshan 215300, China.
First People's Hospital of Kunshan · CNChongqing Cancer Hospital · CNCentral South University · CNJiangsu University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNA-21 was upexpressed in gastric cancer (GC) indicating that it is a potential diagnostic biomarker for GC. In this study, 50 GC patients and 50 healthy controls were recruited. miR-21 levels in serum and peripheral blood mononuclear cells (PBMCs) were quantified using quantitative real-time PCR. CA199, and CEA were measured using electrochemiluminescence assay. The sensitivity and specificity of circulating miR-21, CA199 and CEA in GC diagnosis, the correlation of circulating miR-21 to clinicopathological features, and the diagnostic value of miR-21 in different GC stages were determined. The levels of miR-21 in both serum and PBMCs increased significantly in GC patients comparing to healthy controls; however, no correlation was observed between circulating miR-21 level and clinicopathological features. The sensitivity and specificity of miR-21 in serum and PBMCs, and CA199 and CEA in GC diagnosis were 88.4%, 79.6%, 81.3%, 73.4%, 60.5%, 55.9%, and 68.6%, 59.3%, respectively. The positive prediction rates of circulating miR-21 in GC stages I to IV were all around 90%, while those of CA199 and CEA were around or less than 50%. Our data suggest circulating miR-21 (both in serum and in PBMCs) can serve as a good biomarker for GC and could be used in diagnosis of early (stage I) and late GC (stage IV).

Indexed as

AdultAgedAntigens, Tumor-Associated, CarbohydrateBiomarkers, TumorCarcinoembryonic AntigenFemaleHumansMaleMicroRNAsMiddle AgedStomach NeoplasmsAntigens, Tumor-Associated, CarbohydrateBiomarkers, Tumorcarbohydrate antigen 199, humanCarcinoembryonic AntigenMicroRNAsMIRN21 microRNA, human

Identifiers

PMID26063956
PMCPMC4433679
OpenAlexW1974938457

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.